Technology (UPN: 47)
|In-vitro model to simulate digestion|
|Organisation Region||European Union|
|Overview||In-vitro static digestion model to evaluate the bioavailability, bioaccessibility and beneficial effects of proteins, single compounds, complex formulations and nanoparticles.|
The proposed model is able to simulate the 3 compartments: Mouth/saliva; stomach and bowel. It enables to measure individual compartments as well as the result after complete digestion. It enbales as well to follow the resorption and the primary metabolism if requested.The proposed model simulates not only stomach and small intestine but also the digestion by saliva.
The model is a static which simulates pH, enzyme content and others and, thus, allows a good time performance of the digestion within a few days. It can be used under fasted state as well as under fed state conditions with or without an FDA recommended high fat meal matrix. An easy to handle model, which has shown good correlation to human clinical studies. So, it is a reliable method to be used in research and pre -development as well for formulation purposes.
It can measure:
It is a ready- to-use method which means that it needs no complicated set up nor a specific instrumentation other than the typical analytical instrumentation to measure amino acids or to observe cell changes or fluid composition.
The model does not include the microflora, which the company considers to be an advantage as microflora is too individual to simulate. But if customer needs it for his purposes then the addition of selective strains on step can be envisioned.
It involves no experimental animals at all and needs no additional developmental work. It can be adapted to nearly every desired physiological situation. Moreover, this model is a rapid method which is very cost-effective (considerably below current animal tests).
Up to now there have been several pharmaceuticals and nutraceuticals which have been tested with the model for their behaviour during gastrointestinal passage and hepatic metabolism after adsorption. The model allowed to explain unwanted side-reactions which occurred in individuals during clinical studies.
Evaluation of digestibility of pharmaceuticals, Evaluation of digestibility of nutrients or food active ingredients, Cytotoxicity assessment of hazardous substances or polluants.
Static and thus, comprehensible simulation of the physiological conditions of the human gastrointestinal tract. Total digestion as well as specific digestive steps possible. High variability of digestive conditions possible (e.g. starving and fed conditions, use of a high fat diet according to FDA possible), vegetarian diet and others. Free of individual variations as present in experimental animals or human volunteers. Applicable for tests in very early stages of development. This helps to reduce total development periods and costs. Examination of beneficial and/or unwanted toxic (side) effects possible. Quick results within some working days. Depending on the demand and experimental design, a high throughput is possible.
|Innovator||Company is willing to provide contract services for Research and Development, as well as licensing opportunities.|
Click here to request the identity of an Innovator free of charge. You must accept our Scout Terms before Requesting Identity. If the Innovator accepts your Request, we will disclose the Innovator's identity to you in a Disclosure Report.
You may not contact a Disclosed Innovator for 12 months from the Disclosure Date, unless introduced by us (select 'Request Introduction' after Disclosure) or if you notify us of 'Prior Contact' or 'Prior Knowledge' in the Member's Area.
See 4 Steps above for our full process and refer to our Scout Terms for full details.